TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7892492

Group type: EXPERIMENTAL
Intervention: Gadolinium-enhanced magnetization transfer (MT) MR imaging
Number of subjects: 86

Group type: COMPARATOR
Intervention: Conventional T1-weighted MR imaging
Number of subjects: 86

Group type: COMPARATOR
Intervention: Non-enhanced T1-weighted MT images
Number of subjects: 86
Study: 2796369

Group type: EXPERIMENTAL
Intervention: Topical vancomycin applied to cut sternal edges (group V)
Number of subjects: 416

Group type: COMPARATOR
Intervention: Control group (no topical vancomycin, only hemostatic paste)
Number of subjects: 416
Study: 273143

Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Intrathecal cytosine arabinoside
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no CNS prophylaxis)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Overall (both intrathecal chemotherapy groups)
Number of subjects: 32
Study: 31392826

Group type: EXPERIMENTAL
Intervention: Five long noncoding RNAs (AATK‐AS1, C10orf91, LINC00162, LINC00200, and LINC00501) used to predict overall survival (OS) based on gene expression and regression coefficients.
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Subgroup analysis of the five lncRNAs in early-stage liver cancer.
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Association of the five lncRNAs with immune cell infiltration.
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: KEGG pathway enrichment analysis of coexpressed modules.
Number of subjects: 313
Study: 27489178

Group type: EXPERIMENTAL
Intervention: Migraine-specific medication (MSM)
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Over-the-counter analgesic (OTC)
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Opiate/barbiturate
Number of subjects: 337
Study: 25195547

Group type: EXPERIMENTAL
Intervention: n-3 fish oil 3000 mg/day
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 23972905

Group type: EXPERIMENTAL
Intervention: Diet group
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 243

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 243
Study: 21892200

Group type: EXPERIMENTAL
Intervention: Antofloxacin (400 mg on day 1 and 200 mg on days 2 to 5)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Theophylline (100 mg twice a day and morning dose 200 mg on days 1 and 5)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Theophylline plus antofloxacin
Number of subjects: 12
Study: 19515236

Group type: EXPERIMENTAL
Intervention: Oral metronidazole
Number of subjects: 53

Group type: COMPARATOR
Intervention: Vaginal metronidazole
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Both oral and vaginal metronidazole
Number of subjects: 53
Study: 18028134

Group type: EXPERIMENTAL
Intervention: Improved bone marrow culture cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow aspirate and cultured bone marrow cells
Number of subjects: 0
Study: 15040827

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 or 120 mg/day for 3 years
Number of subjects: 7705
Study: 11338965

Group type: EXPERIMENTAL
Intervention: Parent-training intervention (Preparing for the Drug Free Years)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 209
Study: 9215438

Group type: EXPERIMENTAL
Intervention: Occupational injury interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quasi-experimental studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative studies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simple quasi-experimental designs
Number of subjects: 0

Group type: COMPARATOR
Intervention: More elaborate quasi-experimental designs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized controlled trials
Number of subjects: 0
Study: 8432448

Group type: EXPERIMENTAL
Intervention: Cholecystokinin octapeptide 5 ng/kg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cholecystokinin octapeptide 10 ng/kg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cholecystokinin octapeptide 20 ng/kg
Number of subjects: 14
Study: 3307520

Group type: EXPERIMENTAL
Intervention: 7.5 mg midazolam
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 15 mg midazolam
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 30198774

Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 130

Group type: COMPARATOR
Intervention: Conventional education
Number of subjects: 130
Study: 31278067

Group type: EXPERIMENTAL
Intervention: Epigallocatechin gallate (400 mg capsule, orally once daily for 4 weeks, then twice daily for 4 weeks, then three times daily for 40 weeks)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo (mannitol, same dosing schedule as epigallocatechin gallate)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Epigallocatechin gallate
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 28544992

Group type: EXPERIMENTAL
Intervention: USL261 2.5mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: USL261 5.0mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: USL261 (both doses)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: USL261
Number of subjects: 30
Study: 25499545

Group type: EXPERIMENTAL
Intervention: Vitamin A (50,000 IU)
Number of subjects: 22955

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22955
Study: 23613014

Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 20693299

Group type: EXPERIMENTAL
Intervention: Paclitaxel (Taxol) (50 mg/mq) combined with non-pegylated liposomal anthracycline (25 mg/mq)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Docetaxel (Taxotere) (30 mg/mq) combined with non-pegylated liposomal anthracycline (25 mg/mq)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Paclitaxel (Taxol) and docetaxel (Taxotere) combined with non-pegylated liposomal anthracycline
Number of subjects: 56
Study: 19156515

Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD) 40 mg/m² every 4 weeks for 6-9 cycles and weekly trastuzumab (4 mg/kg loading dose, then 2 mg/kg)
Number of subjects: 16
Study: 16157451

Group type: COMPARATOR
Intervention: TLR4 Asp299Gly polymorphism in controls
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Asp/Gly and Gly/Gly genotypes
Number of subjects: 577
Study: 15373006

Group type: EXPERIMENTAL
Intervention: Training in a classification system for acute low back pain (1-day training session)
Number of subjects: 45
Study: 11465562

Group type: EXPERIMENTAL
Intervention: Alfentanil at a plasma concentration of 100 ng/ml
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 14
Study: 9794957

Group type: EXPERIMENTAL
Intervention: Palivizumab
Number of subjects: 0
Study: 7997427

Group type: EXPERIMENTAL
Intervention: Maintenance dose of digoxin administered at 24‐h intervals for 7 days (study group, n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group with no change in the 12‐h dosage interval (n = 15)
Number of subjects: 30
Study: 3375576

Group type: EXPERIMENTAL
Intervention: 405 mg elemental calcium as a salt linked to an amino acid precursor
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 405 mg CaC12
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1000 mg Ca as Ca gluconolactate and carbonate
Number of subjects: 20
Study: 29932414

Group type: EXPERIMENTAL
Intervention: Ticagrelor (fed condition)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AR-C124910XX (fed condition)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ticagrelor and AR-C124910XX (female subjects)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ticagrelor and AR-C124910XX (Chinese subjects)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 0
Study: 29683370

Group type: EXPERIMENTAL
Intervention: Bao Khi Khang tablets combined with standard therapeutic protocol (Antimicrobial+Corticosteroids+Bronchodilator+Mucolytic drugs)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard therapeutic protocol (Antimicrobial+Corticosteroids+Bronchodilator+Mucolytic drugs)
Number of subjects: 60
Study: 26733764

Group type: EXPERIMENTAL
Intervention: BCAA supplementation
Number of subjects: 17

Group type: COMPARATOR
Intervention: CHO supplementation
Number of subjects: 17
Study: 25711325

Group type: EXPERIMENTAL
Intervention: ART-naïve participants in the START trial
Number of subjects: 4601

Group type: EXPERIMENTAL
Intervention: MSM
Number of subjects: 4601

Group type: EXPERIMENTAL
Intervention: Participants from South America/Mexico and North America
Number of subjects: 4601

Group type: EXPERIMENTAL
Intervention: Heterosexual men and women from Africa
Number of subjects: 4601

Group type: EXPERIMENTAL
Intervention: Participants with CLS-D
Number of subjects: 4601

Group type: EXPERIMENTAL
Intervention: Knowledge of ART impact on transmission risk
Number of subjects: 4601
Study: 22987059

Group type: EXPERIMENTAL
Intervention: Automatic noninvasive analysis method based on single-channel nasal airflow signal
Number of subjects: 41

Group type: COMPARATOR
Intervention: Gold-standard esophageal pressure scores
Number of subjects: 41
Study: 20931096

Group type: EXPERIMENTAL
Intervention: Enoxaparin (ENOX)
Number of subjects: 498

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 498
Study: 18184240

Group type: EXPERIMENTAL
Intervention: Mask group (received transparent anesthesia masks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Informed group (received conventional verbal information only)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mask group
Number of subjects: 50

Group type: COMPARATOR
Intervention: Informed group
Number of subjects: 50
Study: 16482200

Group type: EXPERIMENTAL
Intervention: Intracavernosal alprostadil (PGE1) 4 microg (1-8) and sildenafil 50 mg/day
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Low-dose Trimix (20 U) 2-3 times/week and sildenafil 50 mg/day
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Penile doppler studies
Number of subjects: 22
Study: 14674490

Group type: EXPERIMENTAL
Intervention: Microabrasion slurry (Opalustre) for 20 seconds with a load of 200 g
Number of subjects: 16

Group type: COMPARATOR
Intervention: Abrasive cleaning paste (Pell-ex) for 20 seconds with a load of 200 g
Number of subjects: 16
Study: 9696455

Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 8203510

Group type: EXPERIMENTAL
Intervention: Norepinephrine (NE) infusion
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Angiotensin II (ANG II) infusion
Number of subjects: 29

Group type: COMPARATOR
Intervention: Guanadrel (G) to suppress SNS activity
Number of subjects: 29
Study: 2685220

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 795437

Group type: EXPERIMENTAL
Intervention: Trasylol (aprotinin) treatment
Number of subjects: 4686
Study: 31514507

Group type: EXPERIMENTAL
Intervention: Attending Heart School
Number of subjects: 47907
Study: 31217388

Group type: EXPERIMENTAL
Intervention: Combined noxious (CPM) and non-noxious (TENS) stimuli
Number of subjects: 44

Group type: COMPARATOR
Intervention: Non-noxious stimuli (TENS)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Noxious stimuli (CPM)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 44
Study: 28747329

Group type: EXPERIMENTAL
Intervention: Orange juice (OJ) consumption after 7 days of training cessation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Orange juice (OJ) consumption during training
Number of subjects: 10
Study: 23362861

Group type: EXPERIMENTAL
Intervention: Peer education intervention
Number of subjects: 652

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 652
Study: 20673244

Group type: EXPERIMENTAL
Intervention: Patient-physician agreement on whether CHD was discussed
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Patient-physician agreement on discussion content (pros vs cons)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Patient-physician agreement on physicians' recommendations
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Patient-physician agreement on final decisions to take medication
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Patient-physician agreement on final decisions to change lifestyle
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Patient-physician agreement on degree of involvement in decision making
Number of subjects: 157
Study: 19139673

Group type: EXPERIMENTAL
Intervention: Experimental booklet (The Neck Book)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Traditional booklet
Number of subjects: 187

Group type: COMPARATOR
Intervention: No booklet
Number of subjects: 187
Study: 16779656

Group type: EXPERIMENTAL
Intervention: Telephone support behavioral intervention (up to 12 scheduled psycho-educational calls over 6 months)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Assessment-only control condition
Number of subjects: 177
Study: 15274369

Group type: EXPERIMENTAL
Intervention: NAC with UFT (tegafur plus uracil)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Control (no-NAC)
Number of subjects: 295
Study: 11457560

Group type: EXPERIMENTAL
Intervention: TAB9 (0.2 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: TAB9 (1 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: TAB9 (0.2 mg and 1 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 9886322

Group type: EXPERIMENTAL
Intervention: Epoetin alpha (150 U/kg/d s.c. for 8 weeks)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Epoetin alpha
Number of subjects: 87
Study: 7869317

Group type: EXPERIMENTAL
Intervention: Initial orthopedic consultation waiting time
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Knee replacement surgery waiting time
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Average acceptable surgical waiting time
Number of subjects: 145
Study: 2405740

Group type: EXPERIMENTAL
Intervention: Nitrous oxide 50% in oxygen
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Nitrous oxide 70% in oxygen
Number of subjects: 165

Group type: COMPARATOR
Intervention: 100% oxygen
Number of subjects: 165

Group type: COMPARATOR
Intervention: Room air
Number of subjects: 165
Study: 788746

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 21

Group type: COMPARATOR
Intervention: Practolol
Number of subjects: 21
Study: 31485880

Group type: EXPERIMENTAL
Intervention: Group spiritual therapy (8 sessions, 45-60 minutes each, twice a week)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 50
Study: 30389671

Group type: EXPERIMENTAL
Intervention: Statin prescriptions
Number of subjects: 70793

Group type: EXPERIMENTAL
Intervention: ACE inhibitor (ACEI)/angiotensin receptor blocker (ARB) prescriptions
Number of subjects: 70793

Group type: COMPARATOR
Intervention: Proton pump inhibitor (PPI) prescriptions (control)
Number of subjects: 70793

Group type: EXPERIMENTAL
Intervention: Antiplatelet prescriptions
Number of subjects: 70793
Study: 26365745

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) withdrawal
Number of subjects: 40
Study: 26243165

Group type: EXPERIMENTAL
Intervention: Lercanidipine + losartan (20 mg/day + 100 mg/day)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Barnidipine + losartan (20 mg/day + 100 mg/day)
Number of subjects: 144
Study: 23519566

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Waiting list condition (control)
Number of subjects: 37
Study: 21457392

Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid (TA) treatment (750 mg/d for 4 weeks)
Number of subjects: 32

Group type: COMPARATOR
Intervention: No oral tranexamic acid treatment (Control)
Number of subjects: 32
Study: 19042105

Group type: EXPERIMENTAL
Intervention: Olanzapine or risperidone treatment after 16 weeks
Number of subjects: 102

Group type: COMPARATOR
Intervention: Baseline (drug naive)
Number of subjects: 102
Study: 16940486

Group type: EXPERIMENTAL
Intervention: Xenogenic graft material (Gent‐tech) used to fill extraction sockets
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (natural healing without graft)
Number of subjects: 39
Study: 16540546

Group type: EXPERIMENTAL
Intervention: Low-dose D-penicillamine
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: High-dose D-penicillamine
Number of subjects: 134
Study: 14689405

Group type: EXPERIMENTAL
Intervention: Propofol (100-200 microg/kg/min)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Ketamine (50-75 microg/kg/min)
Number of subjects: 41
Study: 10522184

Group type: EXPERIMENTAL
Intervention: Implant-retained overdenture (IRO-group, 2 endosseous implants)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Complete denture (CD-group)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Complete denture (CD-group) with retreatment option
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Implant-retained overdenture (IRO-group)
Number of subjects: 121
Study: 7547854

Group type: EXPERIMENTAL
Intervention: Fe-fortified weaning cereal (200 mg Fe/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fe-fortified weaning cereal (500 mg Fe/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fe-fortified bread (65 mg Fe/kg flour)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fe-fortified infant formula (12 mg Fe/l)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-Fe-fortified weaning cereal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-Fe-fortified bread
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-Fe-fortified infant formula
Number of subjects: 0
Study: 2269248

Group type: EXPERIMENTAL
Intervention: 30 mumol zinc, 6.4 mmol calcium and 500 mumol inositol hexaphosphate (phytic acid)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Solution not containing phytic acid (previously observed)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Addition of amino acids to the solution
Number of subjects: 11
Study: 35825

Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31496160

Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg, 3 times a day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 30800820

Group type: EXPERIMENTAL
Intervention: Web-based dermatology teaching module
Number of subjects: 40
Study: 25760554

Group type: EXPERIMENTAL
Intervention: LFQS monotherapy
Number of subjects: 15

Group type: COMPARATOR
Intervention: Combined LFQS and 30% GA peeling
Number of subjects: 15
Study: 23585009

Group type: EXPERIMENTAL
Intervention: Ibutilide 1 mg (repeated if AF/AFL not converted after 10 min)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Propafenone 70 mg (repeated if AF/AFL persisted after 10 min)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Ibutilide
Number of subjects: 99

Group type: COMPARATOR
Intervention: Propafenone
Number of subjects: 99
Study: 20492587

Group type: EXPERIMENTAL
Intervention: Orthotic insoles (n=73)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Control group (no orthotic insoles, n=147)
Number of subjects: 228
Study: 19781418

Group type: COMPARATOR
Intervention: Ad hoc PCI
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Delayed PCI (2 hours after loading)
Number of subjects: 199
Study: 16769962

Group type: EXPERIMENTAL
Intervention: Cognitively impaired ALS patients (ALSci)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cognitively intact ALS patients
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10

Group type: COMPARATOR
Intervention: Alzheimer disease patients
Number of subjects: 10
Study: 15579760

Group type: EXPERIMENTAL
Intervention: Pioglitazone (≤45 mg/d)
Number of subjects: 1199

Group type: COMPARATOR
Intervention: Metformin (≤850 mg, three times daily)
Number of subjects: 1199
Study: 11416112

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 556

Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 556
Study: 9015015

Group type: EXPERIMENTAL
Intervention: U technique
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard technique
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: U technique and Standard technique
Number of subjects: 200
Study: 8338039

Group type: EXPERIMENTAL
Intervention: Home trials (H1, H2, H3)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Clinical trials (C1, C2, C3)
Number of subjects: 10
Study: 3486596

Group type: EXPERIMENTAL
Intervention: Single-dose trimethoprim-sulfamethoxazole prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30909715

Group type: EXPERIMENTAL
Intervention: Food service implementation intervention
Number of subjects: 395
Study: 28444742

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 26030168

Group type: EXPERIMENTAL
Intervention: Adults purchasing goods for others
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Costly giving (sharing their own candy with a puppet)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-costly giving (sharing the experimenter's candy with a puppet)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Costly giving vs. Non-costly giving
Number of subjects: 0
Study: 23174861

Group type: EXPERIMENTAL
Intervention: Nighttime snacking (192.4 ± 18.3 kcal)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Nighttime snacking
Number of subjects: 11

Group type: COMPARATOR
Intervention: Daytime snacking
Number of subjects: 11
Study: 21763463

Group type: EXPERIMENTAL
Intervention: Balneotherapy with thermal water at 38°C for 15 sessions of 30 minutes
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (22 obese and 20 hypertensive patients)
Number of subjects: 42